Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Acute Agitation and Aggression Treatment Market Research Report: Information by Drug Class (First-Generation Anti-Psychotics, Second-Generation Anti-Psychotics, Benzodiazepines, and Others), by Route of Administration (Oral, Intramuscular, and Others), by Indication (Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-induced Agitation and Aggression, Alcohol Withdrawal, and Others), by End User (Hospitals & Clinics, Psychiatric Care Facilities, and Others), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—For


ID: MRFR/Pharma/7365-CR | 128 Pages | Author: Kinjoll Dey| October 2023

Acute Agitation and Aggression Treatment Market Segmentation


Acute Agitation and Aggression Treatment Market Drug Class Outlook (USD Billion, 2019-2032)



  • First-Generation Anti-Psychotics

  • Second-Generation Anti-Psychotics

  • Benzodiazepines

  • Others


Acute Agitation and Aggression Treatment Market Route of Administration Outlook (USD Billion, 2019-2032)



  • Oral

  • Intramuscular

  • Others


Acute Agitation and Aggression Treatment Market Indication Outlook (USD Billion, 2019-2032)



  • Schizophrenia

  • Dementia

  • Bipolar Disorder

  • Depression

  • Drug-induced Agitation and Aggression

  • Alcohol Withdrawal

  • Others


Acute Agitation and Aggression Treatment Market End User Outlook (USD Billion, 2019-2032)



  • Hospitals & Clinics

  • Psychiatric Care Facilities

  • Others


Acute Agitation and Aggression Treatment Regional Outlook (USD Billion, 2019-2032)




  • North America Outlook (USD Billion, 2019-2032)


    • North America Acute Agitation and Aggression Treatment by Drug Class

      • First-Generation Anti-Psychotics

      • Second-Generation Anti-Psychotics

      • Benzodiazepines

      • Others




    • North America Acute Agitation and Aggression Treatment by Route of Administration 

      • Oral

      • Intramuscular

      • Others




    • North America Acute Agitation and Aggression Treatment by Indication

      • Schizophrenia

      • Dementia

      • Bipolar Disorder

      • Depression

      • Drug-induced Agitation and Aggression

      • Alcohol Withdrawal

      • Others




    • North America Acute Agitation and Aggression Treatment by End User 

      • Hospitals & Clinics

      • Psychiatric Care Facilities

      • Others



    • US Outlook (USD Billion, 2019-2032)


    • US Acute Agitation and Aggression Treatment by Drug Class

      • First-Generation Anti-Psychotics

      • Second-Generation Anti-Psychotics

      • Benzodiazepines

      • Others




    • US Acute Agitation and Aggression Treatment by Route of Administration 

      • Oral

      • Intramuscular

      • Others




    • US Acute Agitation and Aggression Treatment by Indication

      • Schizophrenia

      • Dementia

      • Bipolar Disorder

      • Depression

      • Drug-induced Agitation and Aggression

      • Alcohol Withdrawal

      • Others




    • US Acute Agitation and Aggression Treatment by End User 

      • Hospitals & Clinics

      • Psychiatric Care Facilities

      • Others



    • Canada Outlook (USD Billion, 2019-2032)


    • Canada Acute Agitation and Aggression Treatment by Drug Class

      • First-Generation Anti-Psychotics

      • Second-Generation Anti-Psychotics

      • Benzodiazepines

      • Others




    • Canada Acute Agitation and Aggression Treatment by Route of Administration 

      • Oral

      • Intramuscular

      • Others




    • Canada Acute Agitation and Aggression Treatment by Indication

      • Schizophrenia

      • Dementia

      • Bipolar Disorder

      • Depression

      • Drug-induced Agitation and Aggression

      • Alcohol Withdrawal

      • Others




    • Canada Acute Agitation and Aggression Treatment by End User 

      • Hospitals & Clinics

      • Psychiatric Care Facilities

      • Others




    • Europe Outlook (USD Billion, 2019-2032)


      • Europe Acute Agitation and Aggression Treatment by Drug Class

        • First-Generation Anti-Psychotics

        • Second-Generation Anti-Psychotics

        • Benzodiazepines

        • Others




      • Europe Acute Agitation and Aggression Treatment by Route of Administration 

        • Oral

        • Intramuscular

        • Others




      • Europe Acute Agitation and Aggression Treatment by Indication

        • Schizophrenia

        • Dementia

        • Bipolar Disorder

        • Depression

        • Drug-induced Agitation and Aggression

        • Alcohol Withdrawal

        • Others




      • Europe Acute Agitation and Aggression Treatment by End User 

        • Hospitals & Clinics

        • Psychiatric Care Facilities

        • Others




      • Germany Outlook (USD Billion, 2019-2032)


      • Germany Acute Agitation and Aggression Treatment by Drug Class

        • First-Generation Anti-Psychotics

        • Second-Generation Anti-Psychotics

        • Benzodiazepines

        • Others




      • Germany Acute Agitation and Aggression Treatment by Route of Administration 

        • Oral

        • Intramuscular

        • Others




      • Germany Acute Agitation and Aggression Treatment by Indication

        • Schizophrenia

        • Dementia

        • Bipolar Disorder

        • Depression

        • Drug-induced Agitation and Aggression

        • Alcohol Withdrawal

        • Others




      • Germany Acute Agitation and Aggression Treatment by End User 

        • Hospitals & Clinics

        • Psychiatric Care Facilities

        • Others



      • France Outlook (USD Billion, 2019-2032)


      • France Acute Agitation and Aggression Treatment by Drug Class

        • First-Generation Anti-Psychotics

        • Second-Generation Anti-Psychotics

        • Benzodiazepines

        • Others




      • France Acute Agitation and Aggression Treatment by Route of Administration 

        • Oral

        • Intramuscular

        • Others




      • France Acute Agitation and Aggression Treatment by Indication

        • Schizophrenia

        • Dementia

        • Bipolar Disorder

        • Depression

        • Drug-induced Agitation and Aggression

        • Alcohol Withdrawal

        • Others




      • France Acute Agitation and Aggression Treatment by End User 

        • Hospitals & Clinics

        • Psychiatric Care Facilities

        • Others



      • UK Outlook (USD Billion, 2019-2032)


      • UK Acute Agitation and Aggression Treatment by Drug Class

        • First-Generation Anti-Psychotics

        • Second-Generation Anti-Psychotics

        • Benzodiazepines

        • Others




      • UK Acute Agitation and Aggression Treatment by Route of Administration 

        • Oral

        • Intramuscular

        • Others




      • UK Acute Agitation and Aggression Treatment by Indication

        • Schizophrenia

        • Dementia

        • Bipolar Disorder

        • Depression

        • Drug-induced Agitation and Aggression

        • Alcohol Withdrawal

        • Others




      • UK Acute Agitation and Aggression Treatment by End User

        • Hospitals & Clinics

        • Psychiatric Care Facilities

        • Others



      • Italy Outlook (USD Billion, 2019-2032)


      • Italy Acute Agitation and Aggression Treatment by Drug Class

        • First-Generation Anti-Psychotics

        • Second-Generation Anti-Psychotics

        • Benzodiazepines

        • Others




      • Italy Acute Agitation and Aggression Treatment by Route of Administration 

        • Oral

        • Intramuscular

        • Others




      • Italy Acute Agitation and Aggression Treatment by Indication

        • Schizophrenia

        • Dementia

        • Bipolar Disorder

        • Depression

        • Drug-induced Agitation and Aggression

        • Alcohol Withdrawal

        • Others




      • Italy Acute Agitation and Aggression Treatment by End User

        • Hospitals & Clinics

        • Psychiatric Care Facilities

        • Others



      • Spain Outlook (USD Billion, 2019-2032)


      • Spain Acute Agitation and Aggression Treatment by Drug Class

        • First-Generation Anti-Psychotics

        • Second-Generation Anti-Psychotics

        • Benzodiazepines

        • Others




      • Spain Acute Agitation and Aggression Treatment by Route of Administration 

        • Oral

        • Intramuscular

        • Others




      • Spain Acute Agitation and Aggression Treatment by Indication

        • Schizophrenia

        • Dementia

        • Bipolar Disorder

        • Depression

        • Drug-induced Agitation and Aggression

        • Alcohol Withdrawal

        • Others




      • Spain Acute Agitation and Aggression Treatment by End User

        • Hospitals & Clinics

        • Psychiatric Care Facilities

        • Others



      • Rest Of Europe Outlook (USD Billion, 2019-2032)


      • Rest Of Europe Acute Agitation and Aggression Treatment by Drug Class

        • First-Generation Anti-Psychotics

        • Second-Generation Anti-Psychotics

        • Benzodiazepines

        • Others




      • Rest of Europe Acute Agitation and Aggression Treatment by Route of Administration 

        • Oral

        • Intramuscular

        • Others




      • Rest of Europe Acute Agitation and Aggression Treatment by Indication 

        • Schizophrenia

        • Dementia

        • Bipolar Disorder

        • Depression

        • Drug-induced Agitation and Aggression

        • Alcohol Withdrawal

        • Others




      • Rest of Europe Acute Agitation and Aggression Treatment by End User

        • Hospitals & Clinics

        • Psychiatric Care Facilities

        • Others




      • Asia-Pacific Outlook (USD Billion, 2019-2032)


        • Asia-Pacific Acute Agitation and Aggression Treatment by Drug Class

          • First-Generation Anti-Psychotics

          • Second-Generation Anti-Psychotics

          • Benzodiazepines

          • Others




        • Asia-Pacific Acute Agitation and Aggression Treatment by Route of Administration 

          • Oral

          • Intramuscular

          • Others




        • Asia-Pacific Acute Agitation and Aggression Treatment by Indication

          • Schizophrenia

          • Dementia

          • Bipolar Disorder

          • Depression

          • Drug-induced Agitation and Aggression

          • Alcohol Withdrawal

          • Others




        • Asia-Pacific Acute Agitation and Aggression Treatment by End User

          • Hospitals & Clinics

          • Psychiatric Care Facilities

          • Others




        • Japan Outlook (USD Billion, 2019-2032)


        • Japan Acute Agitation and Aggression Treatment by Drug Class

          • First-Generation Anti-Psychotics

          • Second-Generation Anti-Psychotics

          • Benzodiazepines

          • Others




        • Japan Acute Agitation and Aggression Treatment by Route of Administration 

          • Oral

          • Intramuscular

          • Others




        • Japan Acute Agitation and Aggression Treatment by Indication

          • Schizophrenia

          • Dementia

          • Bipolar Disorder

          • Depression

          • Drug-induced Agitation and Aggression

          • Alcohol Withdrawal

          • Others




        • Japan Acute Agitation and Aggression Treatment by End User

          • Hospitals & Clinics

          • Psychiatric Care Facilities

          • Others




        • China Outlook (USD Billion, 2019-2032)


        • China Acute Agitation and Aggression Treatment by Drug Class

          • First-Generation Anti-Psychotics

          • Second-Generation Anti-Psychotics

          • Benzodiazepines

          • Others




        • China Acute Agitation and Aggression Treatment by Route of Administration 

          • Oral

          • Intramuscular

          • Others




        • China Acute Agitation and Aggression Treatment by Indication

          • Schizophrenia

          • Dementia

          • Bipolar Disorder

          • Depression

          • Drug-induced Agitation and Aggression

          • Alcohol Withdrawal

          • Others




        • China Acute Agitation and Aggression Treatment by End User

          • Hospitals & Clinics

          • Psychiatric Care Facilities

          • Others




        • India Outlook (USD Billion, 2019-2032)


        • India Acute Agitation and Aggression Treatment by Drug Class

          • First-Generation Anti-Psychotics

          • Second-Generation Anti-Psychotics

          • Benzodiazepines

          • Others




        • India Acute Agitation and Aggression Treatment by Route of Administration 

          • Oral

          • Intramuscular

          • Others




        • India Acute Agitation and Aggression Treatment by Indication

          • Schizophrenia

          • Dementia

          • Bipolar Disorder

          • Depression

          • Drug-induced Agitation and Aggression

          • Alcohol Withdrawal

          • Others




        • India Acute Agitation and Aggression Treatment by End User

          • Hospitals & Clinics

          • Psychiatric Care Facilities

          • Others




        • Australia Outlook (USD Billion, 2019-2032)


        • Australia Acute Agitation and Aggression Treatment by Drug Class

          • First-Generation Anti-Psychotics

          • Second-Generation Anti-Psychotics

          • Benzodiazepines

          • Others




        • Australia Acute Agitation and Aggression Treatment by Route of Administration 

          • Oral

          • Intramuscular

          • Others




        • Australia Acute Agitation and Aggression Treatment by Indication

          • Schizophrenia

          • Dementia

          • Bipolar Disorder

          • Depression

          • Drug-induced Agitation and Aggression

          • Alcohol Withdrawal

          • Others




        • Australia Acute Agitation and Aggression Treatment by End User

          • Hospitals & Clinics

          • Psychiatric Care Facilities

          • Others




        • South Korea Outlook (USD Billion, 2019-2032)


        • South Korea Acute Agitation and Aggression Treatment by Drug Class

          • First-Generation Anti-Psychotics

          • Second-Generation Anti-Psychotics

          • Benzodiazepines

          • Others




        • South Korea Acute Agitation and Aggression Treatment by Route of Administration 

          • Oral

          • Intramuscular

          • Others




        • South Korea Acute Agitation and Aggression Treatment by Indication

          • Schizophrenia

          • Dementia

          • Bipolar Disorder

          • Depression

          • Drug-induced Agitation and Aggression

          • Alcohol Withdrawal

          • Others




        • South Korea Acute Agitation and Aggression Treatment by End User

          • Hospitals & Clinics

          • Psychiatric Care Facilities

          • Others




        • Rest of Asia-Pacific Outlook (USD Billion, 2019-2032)


        • Rest of Asia-Pacific Acute Agitation and Aggression Treatment by Drug Class

          • First-Generation Anti-Psychotics

          • Second-Generation Anti-Psychotics

          • Benzodiazepines

          • Others




        • Rest of Asia-Pacific Acute Agitation and Aggression Treatment by Route of Administration 

          • Oral

          • Intramuscular

          • Others




        • Rest of Asia-Pacific Acute Agitation and Aggression Treatment by Indication

          • Schizophrenia

          • Dementia

          • Bipolar Disorder

          • Depression

          • Drug-induced Agitation and Aggression

          • Alcohol Withdrawal

          • Others




        • Rest of Asia-Pacific Acute Agitation and Aggression Treatment by End User

          • Hospitals & Clinics

          • Psychiatric Care Facilities

          • Others




        • Rest of the World Outlook (USD Billion, 2019-2032)


          • Rest of the World Acute Agitation and Aggression Treatment by Drug Class

            • First-Generation Anti-Psychotics

            • Second-Generation Anti-Psychotics

            • Benzodiazepines

            • Others




          • Rest of the World Acute Agitation and Aggression Treatment by Route of Administration 

            • Oral

            • Intramuscular

            • Others




          • Rest of the World Acute Agitation and Aggression Treatment by Indication 

            • Schizophrenia

            • Dementia

            • Bipolar Disorder

            • Depression

            • Drug-induced Agitation and Aggression

            • Alcohol Withdrawal

            • Others




          • Rest of the World Acute Agitation and Aggression Treatment by End User

            • Hospitals & Clinics

            • Psychiatric Care Facilities

            • Others




          • Middle East Outlook (USD Billion, 2019-2032)


          • Middle East Acute Agitation and Aggression Treatment by Drug Class

            • First-Generation Anti-Psychotics

            • Second-Generation Anti-Psychotics

            • Benzodiazepines

            • Others




          • Middle East Acute Agitation and Aggression Treatment by Route of Administration 

            • Oral

            • Intramuscular

            • Others




          • Middle East Acute Agitation and Aggression Treatment by Indication

            • Schizophrenia

            • Dementia

            • Bipolar Disorder

            • Depression

            • Drug-induced Agitation and Aggression

            • Alcohol Withdrawal

            • Others




          • Middle East Acute Agitation and Aggression Treatment by End User

            • Hospitals & Clinics

            • Psychiatric Care Facilities

            • Others




          • Africa Outlook (USD Billion, 2019-2032)


          • Africa Acute Agitation and Aggression Treatment by Drug Class

            • First-Generation Anti-Psychotics

            • Second-Generation Anti-Psychotics

            • Benzodiazepines

            • Others




          • Africa Acute Agitation and Aggression Treatment by Route of Administration 

            • Oral

            • Intramuscular

            • Others




          • Africa Acute Agitation and Aggression Treatment by Indication

            • Schizophrenia

            • Dementia

            • Bipolar Disorder

            • Depression

            • Drug-induced Agitation and Aggression

            • Alcohol Withdrawal

            • Others




          • Africa Acute Agitation and Aggression Treatment by End User

            • Hospitals & Clinics

            • Psychiatric Care Facilities

            • Others




          • Latin America Outlook (USD Billion, 2019-2032)


          • Latin America Acute Agitation and Aggression Treatment by Drug Class

            • First-Generation Anti-Psychotics

            • Second-Generation Anti-Psychotics

            • Benzodiazepines

            • Others




          • Latin America Acute Agitation and Aggression Treatment by Route of Administration 

            • Oral

            • Intramuscular

            • Others




          • Latin America Acute Agitation and Aggression Treatment by Indication

            • Schizophrenia

            • Dementia

            • Bipolar Disorder

            • Depression

            • Drug-induced Agitation and Aggression

            • Alcohol Withdrawal

            • Others




          • Latin America Acute Agitation and Aggression Treatment by End User

            • Hospitals & Clinics

            • Psychiatric Care Facilities

            • Others











Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Modality

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.2.1. Rising prevalence of acute agitation and aggression

4.2.2. Increase in focus on creating awareness about agitation and aggression

4.3. Restraints

4.3.1. Social stigma associated with mental illness

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS

6.1. Overview

6.2. First-Generation Anti-Psychotics

6.3. Second-Generation Anti-Psychotics

6.4. Benzodiazepines

6.5. Others

7. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

7.1. Overview

7.2. Oral

7.3. Intramuscular

7.4. Others

8. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION

8.1. Overview

8.2. Schizophrenia

8.3. Dementia

8.4. Bipolar Disorder

8.5. Depression

8.6. Drug-induced Agitation and Aggression

8.7. Alcohol Withdrawal

8.8. Others

9. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER

9.1. Overview

9.2. Hospitals & Clinics

9.3. Psychiatric Care Facilities

9.4. Others

10. GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY REGION

10.1. Overview

10.1. North America

10.1.1. US

10.1.2. Canada

10.2. Europe

10.2.1. Germany

10.2.2. France

10.2.3. UK

10.2.4. Italy

10.2.5. Spain

10.2.6. Rest of Europe

10.3. Asia-Pacific

10.3.1. China

10.3.2. India

10.3.3. Japan

10.3.4. South Korea

10.3.5. Australia

10.3.6. Rest of Asia-Pacific

10.4. Rest of the World

10.4.1. Middle East

10.4.2. Africa

10.4.3. Latin America

11. COMPETITIVE LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market Share Analysis

11.4. Major Growth Strategy in the Global Acute Agitation and Aggression Treatment Market,

11.5. Competitive Benchmarking

11.6. Leading Players in Terms of Number of Developments in the Global Acute Agitation and Aggression Treatment Market,

11.7. Key developments and Growth Strategies

11.7.1. New Product Launch/Service Deployment

11.7.2. Merger & Acquisitions

11.7.3. Joint Ventures

11.8. Major Players Financial Matrix

11.8.1. Sales & Operating Income, 2022

11.8.2. Major Players R&D Expenditure. 2022

12. COMPANY PROFILES

12.1. Eli Lilly and Company

12.1.1. Company Overview

12.1.2. Financial Overview

12.1.3. Products Offered

12.1.4. Key Developments

12.1.5. SWOT Analysis

12.1.6. Key Strategies

12.2. Pfizer Inc

12.2.1. Company Overview

12.2.2. Financial Overview

12.2.3. Products Offered

12.2.4. Key Developments

12.2.5. SWOT Analysis

12.2.6. Key Strategies

12.3. GlaxoSmithKline plc

12.3.1. Company Overview

12.3.2. Financial Overview

12.3.3. Products Offered

12.3.4. Key Developments

12.3.5. SWOT Analysis

12.3.6. Key Strategies

12.4. Teva Pharmaceutical Industries Ltd

12.4.1. Company Overview

12.4.2. Financial Overview

12.4.3. Products Offered

12.4.4. Key Developments

12.4.5. SWOT Analysis

12.4.6. Key Strategies

12.5. Otsuka Holdings Co., Ltd

12.5.1. Company Overview

12.5.2. Financial Overview

12.5.3. Products Offered

12.5.4. Key Developments

12.5.5. SWOT Analysis

12.5.6. Key Strategies

12.6. VIATRIS INC

12.6.1. Company Overview

12.6.2. Financial Overview

12.6.3. Products Offered

12.6.4. Key Developments

12.6.5. SWOT Analysis

12.6.6. Key Strategies

12.7. Johnson & Johnson Services, Inc

12.7.1. Company Overview

12.7.2. Financial Overview

12.7.3. Products Offered

12.7.4. Key Developments

12.7.5. SWOT Analysis

12.7.6. Key Strategies

12.8. Novartis AG

12.8.1. Company Overview

12.8.2. Financial Overview

12.8.3. Products Offered

12.8.4. Key Developments

12.8.5. SWOT Analysis

12.8.6. Key Strategies

12.9. H. Lundbeck A/S

12.9.1. Company Overview

12.9.2. Financial Overview

12.9.3. Products Offered

12.9.4. Key Developments

12.9.5. SWOT Analysis

12.9.6. Key Strategies

12.10. Amneal Pharmaceuticals LLC

12.10.1. Company Overview

12.10.2. Financial Overview

12.10.3. Products Offered

12.10.4. Key Developments

12.10.5. SWOT Analysis

12.10.6. Key Strategies

13. APPENDIX

13.1. References

13.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SYNOPSIS, 2019–2032

TABLE 2 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, ESTIMATES & FORECAST, 2019–2032 (USD MILLION)

TABLE 3 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 4 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 5 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 6 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 7 NORTH AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 8 NORTH AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 9 NORTH AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 10 NORTH AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 11 US: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 12 US: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 13 US: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 14 US: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 15 CANADA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 16 CANADA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 17 CANADA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 18 CANADA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 1 EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 2 EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 3 EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 4 EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 5 GERMANY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 6 GERMANY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 7 GERMANY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 8 GERMANY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 9 FRANCE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 10 FRANCE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 11 FRANCE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 12 FRANCE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 13 ITALY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 14 ITALY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 15 ITALY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 16 ITALY: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 17 SPAIN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 18 SPAIN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 19 SPAIN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 20 SPAIN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 21 UK: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 22 UK: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 23 UK: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 24 UK: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END UER, 2019–2032 (USD MILLION)

TABLE 25 REST OF EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 26 REST OF EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 27 REST OF EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 28 REST OF EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 29 ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 30 ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 31 ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 32 ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 33 JAPAN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 34 JAPAN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 35 JAPAN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 36 JAPAN: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 37 CHINA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 38 CHINA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 39 CHINA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 40 CHINA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 41 INDIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 42 INDIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 43 INDIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 44 INDIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 45 AUSTRALIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 46 AUSTRALIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 47 AUSTRALIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 48 AUSTRALIA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 49 SOUTH KOREA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 50 SOUTH KOREA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 51 SOUTH KOREA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 52 SOUTH KOREA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 53 REST OF ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 54 REST OF ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 55 REST OF ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 56 REST OF ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 57 REST OF THE WORLD: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 58 REST OF THE WORLD: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 59 REST OF THE WORLD: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 60 REST OF THE WORLD: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 61 MIDDLE EAST: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 62 MIDDLE EAST: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 63 MIDDLE EAST: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 64 MIDDLE EAST: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 65 AFRICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 66 AFRICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 67 AFRICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 68 AFRICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

TABLE 69 LATIN AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY DRUG CLASS, 2019–2032 (USD MILLION)

TABLE 70 LATIN AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019–2032 (USD MILLION)

TABLE 71 LATIN AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY INDICATION, 2019–2032 (USD MILLION)

TABLE 72 LATIN AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, BY END USER, 2019–2032 (USD MILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET

FIGURE 4 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY DRUG CLASS, 2022

FIGURE 5 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY ROUTE OF ADMINISTRATION, 2022

FIGURE 6 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY INDICATION, 2022

FIGURE 7 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY END USER, 2022

FIGURE 8 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 9 NORTH AMERICA: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 10 EUROPE: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 11 ASIA-PACIFIC: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 12 REST OF THE WORLD: ACUTE AGITATION AND AGGRESSION TREATMENT MARKET, SHARE (%), BY REGION, 2022

FIGURE 13 GLOBAL ACUTE AGITATION AND AGGRESSION TREATMENT MARKET: COMPANY SHARE ANALYSIS, 2022 (%)

FIGURE 14 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 ELI LILLY AND COMPANY: SWOT ANALYSIS

FIGURE 16 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 PFIZER INC: SWOT ANALYSIS

FIGURE 18 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 GLAXOSMITHKLINE PLC: SWOT ANALYSIS

FIGURE 20 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 TEVA PHARMACEUTICAL INDUSTRIES LTD: SWOT ANALYSIS

FIGURE 22 OTSUKA HOLDINGS CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 OTSUKA HOLDINGS CO., LTD.: SWOT ANALYSIS

FIGURE 24 VIATRIS INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 VIATRIS INC: SWOT ANALYSIS

FIGURE 26 JOHNSON & JOHNSON SERVICES, INC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 JOHNSON & JOHNSON SERVICES, INC: SWOT ANALYSIS

FIGURE 28 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 NOVARTIS AG: SWOT ANALYSIS

FIGURE 30 H. LUNDBECK A/S: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 H. LUNDBECK A/S: SWOT ANALYSIS

FIGURE 32 AMNEAL PHARMACEUTICALS LLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 AMNEAL PHARMACEUTICALS LLC: SWOT ANALYSIS

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.